Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | POLD1 | P28340 | 1/20 | 0.40 |
| ▸ | POLG | P54098 | 3/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.34 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22765926 | 0.90 | TK1 (0.36) | — | |
| SCHEMBL20879425 | 0.88 | POLA1 (0.41) | POLA1POLBPOLD1POLGP2RY2 | |
| SCHEMBL21029796 | 0.88 | POLA1 (0.41) | POLA1POLBPOLD1POLGP2RY2 | |
| SCHEMBL22765920 | 0.85 | — | — | |
| SCHEMBL18474902 | 0.82 | P2RY2 (0.39) | POLA1POLBPOLD1POLGP2RY2 | |
| SCHEMBL19590285 | 0.82 | POLB (0.43) | POLA1POLBPOLD1POLGP2RY2 | |
| SCHEMBL24111961 | 0.77 | POLA1 (0.40) | POLA1POLBPOLD1POLGP2RY2 | |
| SCHEMBL17207038 | 0.77 | POLA1 (0.40) | POLA1POLBPOLD1POLGP2RY2 | |
| SCHEMBL24239538 | 0.77 | ALDH1A1 (0.40) | — | |
| SCHEMBL24858818 | 0.76 | POLA1 (0.40) | POLA1POLBPOLD1POLGP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815864-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170143751-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143751-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | POLA1 542/4885POLB 224/4885POLD1 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.